Tuberculin

After extensive clinical testing (all the research participants had the negative example of tuberculin in mind) the Hoechst company began to market the compound toward the end of 1910 under the name Salvarsan.

A reactive tuberculin skin test is a contraindication to BCG.

Classification of tuberculin reaction The results of this test must be interpreted carefully.

Esmond R. Long and Florence B. Seibert identified the active agent in tuberculin as a protein.

Heaf test main The Heaf tuberculin skin test was used in the United Kingdom, but discontinued in 2005.

However, the test was unreliable due to impurities in tuberculin which tended to cause false results.

Interferon-γ release assays and tuberculin skin tests are of little use in the developing world. citation citation IGRA have similar limitations in those with HIV.

Koch announced a glycerine extract of the tubercle bacilli as a "remedy" for tuberculosis in 1890, calling it "tuberculin".

Purified protein derivative (PPD) tuberculin is a precipitate of species-nonspecific molecules obtained from filtrates of sterilized, concentrated cultures.

The tuberculin reaction was first described by Robert Koch in 1890.

The UK recommends that interferon-γ testing should be used to help interpret positive Mantoux tests, and repeated tuberculin skin testing must not be done in people who have had BCG vaccinations.

The US recommends that tuberculin skin testing is not contraindicated for BCG-vaccinated persons, and prior BCG vaccination should not influence the interpretation of the test.

This initial skin test, though negative, may stimulate (boost) the body's ability to react to tuberculin in future tests.

This was where Koch’s hoped-for tuberculosis therapeutic agent tuberculin was under study; and Ehrlich had even injected himself with it.

Tuberculosis is more common in developing countries; about 80% of the population in many Asian and African countries test positive in tuberculin tests, while only 5–10% of the US population test positive.